AOCI at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s AOCI?
- Iovance Biotherapeutics, Inc. (IOVA) reported AOCI of $12.65M in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s AOCI changed year-over-year?
- Iovance Biotherapeutics, Inc.'s AOCI increased by 101.0% year-over-year, from $6.29M to $12.65M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s AOCI has grown at a 286.7% compound annual growth rate (CAGR), from $19K to $16.44M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.